share_log

Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Processa Pharmaceuticals | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 04:07

Moomoo AI 已提取核心訊息

Processa Pharmaceuticals reported a net loss of $9.1 million for the nine months ended September 30, 2024, compared to $8.7 million in the same period of 2023. Research and development expenses increased to $5.6 million from $4.5 million, primarily due to costs associated with the NGC-Cap clinical trials. The company ended the quarter with $2.9 million in cash and cash equivalents.The company achieved significant milestones in its NGC-Cap program, receiving IND clearance in July 2024 and dosing the first patient in its Phase 2 breast cancer trial on October 2, 2024. During the period, Processa strengthened its financial position by raising $6.3 million through a public offering in January and an additional $931,000 through an ATM offering in July 2024.Management acknowledges the need for additional funding to continue operations beyond the next twelve months. The company is exploring various financing options, including equity offerings, debt financing, and strategic partnerships to support its clinical development programs, particularly the ongoing Phase 2 trial of NGC-Cap and advancement of other pipeline candidates NGC-Gem and NGC-Iri.
Processa Pharmaceuticals reported a net loss of $9.1 million for the nine months ended September 30, 2024, compared to $8.7 million in the same period of 2023. Research and development expenses increased to $5.6 million from $4.5 million, primarily due to costs associated with the NGC-Cap clinical trials. The company ended the quarter with $2.9 million in cash and cash equivalents.The company achieved significant milestones in its NGC-Cap program, receiving IND clearance in July 2024 and dosing the first patient in its Phase 2 breast cancer trial on October 2, 2024. During the period, Processa strengthened its financial position by raising $6.3 million through a public offering in January and an additional $931,000 through an ATM offering in July 2024.Management acknowledges the need for additional funding to continue operations beyond the next twelve months. The company is exploring various financing options, including equity offerings, debt financing, and strategic partnerships to support its clinical development programs, particularly the ongoing Phase 2 trial of NGC-Cap and advancement of other pipeline candidates NGC-Gem and NGC-Iri.
Processa Pharmaceuticals報告了截至2024年9月30日的九個月淨虧損910萬美元，而2023年同期的虧損爲870萬美元。研究和開發費用由450萬美元增加到560萬美元，主要是由於與NGC-Cap臨牀試驗相關的成本。公司季度末的現金及現金等價物爲290萬美元。公司在其NGC-Cap項目上取得了重大里程碑，於2024年7月獲得IND批准，並於2024年10月2日對第一位乳腺癌試驗患者進行給藥。在此期間，Processa通過2024年1月的公開發行籌集了630萬美元，並通過2024年7月的ATm發行額外籌集了93.1萬美元，從而增強了其財務狀況。管理層承認需要額外資金以繼續運營，超出接下來的十二個月。該公司正在探索各種融資選項，包括股權發行、債務融資以及戰略合作伙伴關係，以支持其臨牀開發項目，特別是正在進行的NGC-Cap二期試驗以及其他管線候選藥物NGC-Gem和NGC-Iri的推進。
Processa Pharmaceuticals報告了截至2024年9月30日的九個月淨虧損910萬美元，而2023年同期的虧損爲870萬美元。研究和開發費用由450萬美元增加到560萬美元，主要是由於與NGC-Cap臨牀試驗相關的成本。公司季度末的現金及現金等價物爲290萬美元。公司在其NGC-Cap項目上取得了重大里程碑，於2024年7月獲得IND批准，並於2024年10月2日對第一位乳腺癌試驗患者進行給藥。在此期間，Processa通過2024年1月的公開發行籌集了630萬美元，並通過2024年7月的ATm發行額外籌集了93.1萬美元，從而增強了其財務狀況。管理層承認需要額外資金以繼續運營，超出接下來的十二個月。該公司正在探索各種融資選項，包括股權發行、債務融資以及戰略合作伙伴關係，以支持其臨牀開發項目，特別是正在進行的NGC-Cap二期試驗以及其他管線候選藥物NGC-Gem和NGC-Iri的推進。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點